Stock CMMB CHEMOMAB THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
0.6399 USD -2.90% Intraday chart for Chemomab Therapeutics Ltd. -5.90% +25.47%
04-10 Transcript : Chemomab Therapeutics Ltd. - Special Call
03-07 Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Roth MKM Starts Chemomab Therapeutics at Buy, $7 Price Target
MT
Oppenheimer Downgrades Chemomab Therapeutics to Perform From Outperform, Removes $7 Price Target
MT
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $7 From $12, Maintains Outperform Rating
MT
Oppenheimer Adjusts Chemomab Therapeutics' Price Target to $20 From $30, Maintains Outperform Rating
MT
Aegis Capital Initiates Chemomab Therapeutics at Buy Rating With $30 Price Target
MT
Oppenheimer Adjusts Chemomab Therapeutics PT to $30 From $42, Maintains Outperform Rating
MT
CHEMOMAB THERAPEUTICS : Cantor Fitzgerald Initiates Coverage on Chemomab Therapeutics With Overweight Rating, $45 Price Target
MT
CHEMOMAB THERAPEUTICS : Oppenheimer Initiates Coverage on Chemomab Therapeutics With Outperform Rating, $42 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMMB Stock
  4. News Chemomab Therapeutics Ltd.
  5. Analyst Reco.